These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12874518)

  • 21. Gd-encapsulated carbonaceous dots for accurate characterization of tumor vessel permeability in magnetic resonance imaging.
    Wu Y; Yan Y; Gao X; Yang L; Li Y; Guo X; Xie J; Wang K; Sun X
    Nanomedicine; 2019 Oct; 21():102074. PubMed ID: 31376571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.
    Uhl M; Saueressig U; van Buiren M; Kontny U; Niemeyer C; Köhler G; Ilyasov K; Langer M
    Invest Radiol; 2006 Aug; 41(8):618-23. PubMed ID: 16829744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
    AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of vascularity in hepatic tumors: comparison of power Doppler sonography and intraarterial CO(2)-enhanced sonography.
    Chen RC; Chen WT; Tu HY; Cheng NY; Wang CK; Liao LY; Wang CS; Chen PH
    AJR Am J Roentgenol; 2002 Jan; 178(1):67-73. PubMed ID: 11756089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content.
    Farace P; Merigo F; Fiorini S; Nicolato E; Tambalo S; Daducci A; Degrassi A; Sbarbati A; Rubello D; Marzola P
    Eur J Radiol; 2011 Apr; 78(1):52-9. PubMed ID: 19443159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor vascularization in experimental melanomas: correlation between unenhanced and contrast enhanced power Doppler imaging and histological grading.
    Schroeder RJ; Hauff P; Bartels T; Vogel K; Jeschke J; Hidajat N; Maeurer J
    Ultrasound Med Biol; 2001 Jun; 27(6):761-71. PubMed ID: 11516536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging.
    Thoeny HC; De Keyzer F; Vandecaveye V; Chen F; Sun X; Bosmans H; Hermans R; Verbeken EK; Boesch C; Marchal G; Landuyt W; Ni Y
    Radiology; 2005 Nov; 237(2):492-9. PubMed ID: 16192323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring Vascular Disrupting Therapy in a Rabbit Liver Tumor Model: Relationship between Tumor Perfusion Parameters at IVIM Diffusion-weighted MR Imaging and Those at Dynamic Contrast-enhanced MR Imaging.
    Joo I; Lee JM; Grimm R; Han JK; Choi BI
    Radiology; 2016 Jan; 278(1):104-13. PubMed ID: 26200601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic contrast-enhanced ultrasound parametric maps to evaluate intratumoral vascularization.
    Pitre-Champagnat S; Leguerney I; Bosq J; Peronneau P; Kiessling F; Calmels L; Coulot J; Lassau N
    Invest Radiol; 2015 Apr; 50(4):212-7. PubMed ID: 25275834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contrast ultrasonography: necessity of linear data processing for the quantification of tumor vascularization.
    Peronneau P; Lassau N; Leguerney I; Roche A; Cosgrove D
    Ultraschall Med; 2010 Aug; 31(4):370-8. PubMed ID: 20577941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic MRI in indirect estimation of microvessel density, histologic grade, and prognosis in colorectal adenocarcinomas.
    Tuncbilek N; Karakas HM; Altaner S
    Abdom Imaging; 2004; 29(2):166-72. PubMed ID: 15290941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: correlation with histological microvessel density.
    Lee HJ; Rha SY; Chung YE; Shim HS; Kim YJ; Hur J; Hong YJ; Choi BW
    Magn Reson Med; 2014 Apr; 71(4):1554-8. PubMed ID: 23798038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
    Akisik MF; Sandrasegaran K; Bu G; Lin C; Hutchins GD; Chiorean EG
    Radiology; 2010 Aug; 256(2):441-9. PubMed ID: 20515976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice.
    Persigehl T; Bieker R; Matuszewski L; Wall A; Kessler T; Kooijman H; Meier N; Ebert W; Berdel WE; Heindel W; Mesters RM; Bremer C
    Radiology; 2007 Aug; 244(2):449-56. PubMed ID: 17562810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment and monitoring tumor vascularity with contrast-enhanced ultrasound maximum intensity persistence imaging.
    Pysz MA; Foygel K; Panje CM; Needles A; Tian L; Willmann JK
    Invest Radiol; 2011 Mar; 46(3):187-95. PubMed ID: 21150790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraoperative power Doppler ultrasonography with a contrast-enhancing agent for intracranial tumors.
    Kanno H; Ozawa Y; Sakata K; Sato H; Tanabe Y; Shimizu N; Yamamoto I
    J Neurosurg; 2005 Feb; 102(2):295-301. PubMed ID: 15739558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of dynamic contrast-enhanced MRI and correlation with tumor angiogenesis in bladder cancer.
    Tuncbilek N; Kaplan M; Altaner S; Atakan IH; Süt N; Inci O; Demir MK
    AJR Am J Roentgenol; 2009 Apr; 192(4):949-55. PubMed ID: 19304699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlative dynamic contrast MRI and microscopic assessments of tumor vascularity in RIP-Tag2 transgenic mice.
    Sennino B; Raatschen HJ; Wendland MF; Fu Y; You WK; Shames DM; McDonald DM; Brasch RC
    Magn Reson Med; 2009 Sep; 62(3):616-25. PubMed ID: 19526501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of single- and dual-tracer pharmacokinetic modeling of dynamic contrast-enhanced MRI data using low, medium, and high molecular weight contrast agents.
    Orth RC; Bankson J; Price R; Jackson EF
    Magn Reson Med; 2007 Oct; 58(4):705-16. PubMed ID: 17899608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].
    Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.